top of page

Free Biopharma Daily Stock Updates - 07/22/21

  • Writer: BPIQ
    BPIQ
  • Jul 22, 2021
  • 2 min read

$XBI $127.97 -1.8%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$HGEN -0.1% Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab. source


Pipeline Updates

$CYCN -2.4% Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC). source


$ADVM -2.9% Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema. source


$JAZZ -1.7% National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia. source


$NGM -2.5% NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. source


$EVLO -22.7% Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021. source


$RDHL -1.1% RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex. source


$ADMS -2.0% Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101. source


$RDUS -3.4% Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study. source


$GLYC -2.3% Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients. source


$CBIO -4.4% Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies. source


$RYTM -2.8% Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel. source


$ADAG +4.0% Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab). source


$GBT -3.6% GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD). source


$ARVN +9.0% Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471. source


$MCRB -61.8% Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis. source


$LABP -0.8% Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021.


$ANNX -3.3% Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases . source


$PSTV -1.7% Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT™-GBM Trial. source


$ERYP +17.0% ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients. source


Financial Updates

$TCON -24.5% TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million. source


$XENT -1.3% Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan. source


Posted by FS

 
 
 

Comments

bottom of page